Flow Cytometry CD45 Gating for Immunophenotyping of Acute

Total Page:16

File Type:pdf, Size:1020Kb

Flow Cytometry CD45 Gating for Immunophenotyping of Acute Leukemia (1997) 11, 1878–1886 1997 Stockton Press All rights reserved 0887-6924/97 $12.00 Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia F Lacombe, F Durrieu, A Briais, P Dumain, F Belloc, E Bascans, J Reiffers, MR Boisseau and Ph Bernard Laboratoire d’He´matologie, Service des Maladies du Sang, Hoˆpital du Haut-Le´veˆque, Pessac, France A flow cytometry method has been introduced into the routine age values within the malignant blast cell populations or investigation of whole bone marrow samples following red within the total nucleated cells present in each sample. In blood cell lysis on the basis of a primary CD45/side scatter (SSC) gating procedure. Blast cells were first identified by order to give numbers of malignant cells and proportions of CD45/SSC gating in 74 cases of acute myeloid leukemia (AML) cells within this cohort, a reliable practical discrimination and the results were compared to a conventional FSC/SSC gat- between malignant blasts and normal cell types would be ing procedure and to MGG-staining smears. The percentages required. In this paper, as previously recommended by of blast cells in these samples as defined by the morphological Borowitz et al,6 we suggest that such a discrimination can be analysis of MGG smears correlated better with the values readily facilitated by introducing primary gating for CD45 determined by CD45/SSC gating (r 5 0.94) than with the blast antigen expression and side scatter (CD45/SSC). We also sug- cell counts recorded with FSC/SSC gating (r 5 0.76). These findings were not surprising because while CD45 expression gest that this step should replace the first gating step for for- was regularly lower on leukemic blasts than on normal lymph- ward scatter and side scatter (FSC/SSC), as this latter procedure oid and monocytic cells, the FCS/SSC characteristics of these does not discriminate well between leukemic blasts, lympho- populations were overlapping. In 53 samples, the blast cell cytes and monocytes. populations were also analyzed with a panel of FITC-conju- In this paper we present the application of double and triple gated monoclonal antibodies that were utilized in double labe- ling with CD45-PE. We show that the CD45/SSC gating pro- immunofluorescence (IF) analysis of bone marrow samples cedure improved phenotypic determination of the blast cells in taken from patients during the presentation of AML. With the three ways: (1) by discriminating between leukemic blast cells systematic use of leukocyte common antigen (CD45) marker and residual normal cells; (2) by excluding normal cells from in combination with lineage-specific markers, a good dis- the phenotypic analysis of leukemic blast cells; and (3) by crimination can be achieved between the blast cell popu- identifying blast cell heterogeneity in many cases of leukemia lations and the normal cells. This discrimination is based on on the basis of different CD45 display. Moreover, this immuno- phenotyping procedure on whole bone marrow samples also the fact that the precursor cells in the bone marrow, as well allowed an efficient discrimination between the various cell lin- as the leukemias which derive from these cell types, express eages and facilitated the analysis of leukemic blasts present in low and intermediate values of CD45, while lymphocytes and low proportions. monocytes express high levels of CD45.7 Keywords: acute myeloid leukemia; immunophenotyping; CD45; We also present evidence that with conventional FSC/SSC flow cytometry gating miscalculations of blast cell percentages can occur, which can lead to an increase in both false positivity and false negativity in the percent values of leukemic blasts expressing Introduction different antigens. Furthermore, the use of CD45/SSC gating facilitates the expression of results, primarily gated on The characterization of acute leukemias is based on a multi- CD45low blast cells, in a uniform manner that provides similar parametric analysis which includes clinical features, cell mor- observations in lysed whole bone marrow and in enriched phology, genetics and immunological markers. These markers mononuclear populations following Ficoll separation. Our have been shown to be important for the diagnosis and prog- observation adds to previous findings by Borowitz et al,6 Shah nosis of acute myeloid leukemia (AML), particularly when the et al,7 Stelzer et al8 and Rainer et al9 and indicates that precise lineage of the blast cells cannot be defined by light CD45/SSC gating may provide a common platform for microscopy morphology and cytochemistry.1–3 Recently, both uniform data processing during the immunodiagnosis of AML. the European Group for the Immunological Characterization of Leukemias (EGIL)4 and the European Working Group on Flow Cytometry and Image Analysis5 have identified the most Materials and methods important lineage-specific markers for the myeloid and lymph- oid lineages. Nevertheless, there is still disagreement in two Specimens areas. First, it is not yet decided whether the blast cells should be enriched by Ficoll-density gradient centrifugation prior to Seventy-four bone marrow samples were consecutively col- phenotypic analysis or should be studied in the whole bone lected over a 12-month period from adult patients with a sus- marrow following red cell lysis. While opinions tend to favor pected diagnosis of de novo AML. Bone marrow (2–3 ml) was the study of lysed whole bone marrow, samples are still fre- aspirated into EDTA K3 tubes (Vacutainer; Becton Dickinson, quently Ficolled for cryopreservation and storage. Thus, Pont de Claix, France) and received in the laboratory within phenotypic methods which are suitable for analyzing leu- 1 h of collection. Heparinized samples were not suitable for kemic blast cells following both sample handling procedures the bone marrow lysis method used in our laboratory. could be very useful. The second related issue is that it is not yet agreed whether the results should be expressed as percent- Patient population Correspondence: F Lacombe, Laboratoire d’He´matologie, Hoˆ pital du Haut-Le´veˆque, Avenue Magellan, 33604 Pessac, France; Fax: 33 556 The patients included 38 women and 36 men and their age 55 68 09 ranged from 16 to 84 years (median 58.5). The morphological Received 7 March 1997; accepted 1 August 1997 analysis and differential count (excluding erythroid cells) were Flow cytometry immunophenotyping of AML and CD45/SSC gating F Lacombe et al 1879 performed on May–Gru¨nwald–Giemsa-stained smears by two were adjusted using a CD4-FITC/CD8-PE staining of whole experienced readers. blood lymphocytes and levels for positivity were determined Diagnosis was made according to the FAB classification,10 according to PE- and FITC-conjugated isotypic Ig control cytochemistry and immunophenotyping, as AML0 (n = 8), (IgG1-FITC and IgG1-PE from Coulter). A first step (gate A) AML1 (n = 9), AML2 (n = 23), AML3 (n = 10), AML4 (n = 9), was to exclude debris and fat cells on a FSC/SSC histogram; AML5 (n = 10), AML6 (n = 1), AML7 (n = 1), biphenotypic 10 000 cells were counted in gating A and data were recorded acute leukemia (n = 3) as defined by GEIL.11 in list mode. Immunofluorescence (IF) staining Data analysis IF staining was performed on fresh cells by direct IF as follows. List mode data on viable cells (gate A; see above) were ana- Samples were diluted 5 × 105 cells/ml with AB-positive pooled lyzed using the Coulter Elite (version 4.01) or Coulter System plasma (instead of PBS; see below) and 50 ml were incubated II programs. On the CD45/SSC histograms four gates were set for 30 min at room temperature in the dark with 5 ml of each up: gate L for lymphocytes, M for monocytes, G for granulo- FITC (fluorescein isothiocyanate)-conjugated antibody and cytes and B for blast cells (Figure 1b). As the CD45 reagent 5 ml of PE (phycoerythrin)-conjugated CD45 (Table 1). Diag- was labeled with phycoerythrin (CD45-PE) in each gate, the nosis was confirmed by cytoplasmic markers for myeloperoxi- analysis of IgG1-FITC fluorescence intensity distribution was dase, CD3c and CD22c4,5 or megakaryocytic and erythroid also performed. Fewer than 1% cells were found in the linear markers (CD61, CD41b and glycophorin-A; not shown). regions shown in each monoparametric histogram of Figures Samples were then treated using the Coulter ImmunoPrep 1c and 3. Histograms for a panel of antibodies used were ana- reagent kit and Multi-Q-Prep System (Coutronics, Margency, lyzed using the same settings (ie gate A in Figures 1a or 5a, France) according to the manufacturer’s instructions. The c and gates L, M, G, B in Figures 1b or 5b, d). An example Multi-Q-Prep worked well only in samples diluted with in Figure 1c for the CD33 antigen shows the differential plasma as the admixture of PBS caused cell aggregation. In expression of the four cell sub-populations determined in the the first 21 patients, the FSC/SSC and CD45/SSC histograms CD45/SSC histogram. Other examples from the same sample were analyzed and in the other 53 patients all additional are given in Figure 3 for the CD3, CD19, CD14 and CD7 double IF tests were also performed. antigens. In some cases, the gates could be repositioned using backgating from the staining with the FITC-labeled lineage- specific reagents (eg CD3 for T lymphocytes, CD19 for B lym- Flow cytometry phocytes, CD14 for monocytes, as shown in Figure 3). However, these adjustments were minor. In order to keep the setting and histograms uniform during the Blast cell populations were identified by using either gate studies, a Coulter XL flow cytometer was checked daily with S (Figure 1a) in the FSC/SSC histogram, or gate B in the calibration beads (DNA-Check; Coulter). With 488 nm exci- CD45/SSC histogram (Figure 1b).
Recommended publications
  • Bone Marrow Immunophenotyping by Flow Cytometry in Refractory Cytopenia of Childhood
    Myelodysplastic Syndromes ARTICLES Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood Anna M. Aalbers,1,2 Marry M. van den Heuvel-Eibrink,2 Irith Baumann,3 Michael Dworzak,4 Henrik Hasle,5 Franco Locatelli,6 Barbara De Moerloose,7 Markus Schmugge,8 Ester Mejstrikova,9 Michaela Nováková,9 Marco Zecca,10 C. Michel Zwaan,2 Jeroen G. te Marvelde,1 Anton W. Langerak,1 Jacques J.M. van Dongen,1 Rob Pieters,2 Charlotte M. Niemeyer,11 and Vincent H.J. van der Velden1 1Department of Immunology, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands; 2Department of Pediatric Oncology/Hematology, Sophia Children’s Hospital - Erasmus University Medical Center, Rotterdam, The Netherlands; 3Department of Pathology, Clinical Centre South West, Böblingen Clinics, Germany; 4St. Anna Children’s Hospital and Children’s Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Austria; 5Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark; 6Department of Pediatric Hematology-Oncology, IRCCS Ospedale Bambino Gesù, Rome, University of Pavia, Italy; 7Department of Pediatric Hematology/Oncology, Ghent University Hospital, Ghent, Belgium; 8Department of Hematology, University Children’s Hospital, Zurich, Switzerland; 9Department of Pediatric Hematology/Oncology, Charles University and University Hospital Motol, Prague, Czech Republic; 10Pediatric Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; and 11Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University of Freiburg, Germany ABSTRACT Refractory cytopenia of childhood is the most common type of childhood myelodysplastic syndrome. Because the majority of children with refractory cytopenia have a normal karyotype and a hypocellular bone marrow, differ- entiating refractory cytopenia from the immune-mediated bone marrow failure syndrome (very) severe aplastic anemia can be challenging.
    [Show full text]
  • The AML Guide Information for Patients and Caregivers Acute Myeloid Leukemia
    The AML Guide Information for Patients and Caregivers Acute Myeloid Leukemia Emily, AML survivor Revised 2012 Inside Front Cover A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) wants to bring you the most up-to-date blood cancer information. We know how important it is for you to understand your treatment and support options. With this knowledge, you can work with members of your healthcare team to move forward with the hope of remission and recovery. Our vision is that one day most people who have been diagnosed with acute myeloid leukemia (AML) will be cured or will be able to manage their disease and have a good quality of life. We hope that the information in this Guide will help you along your journey. LLS is the world’s largest voluntary health organization dedicated to funding blood cancer research, advocacy and patient services. Since the first funding in 1954, LLS has invested more than $814 million in research specifically targeting blood cancers. We will continue to invest in research for cures and in programs and services that improve the quality of life for people who have AML and their families. We wish you well. Louis J. DeGennaro, PhD President and Chief Executive Officer The Leukemia & Lymphoma Society Inside This Guide 2 Introduction 3 Here to Help 6 Part 1—Understanding AML About Marrow, Blood and Blood Cells About AML Diagnosis Types of AML 11 Part 2—Treatment Choosing a Specialist Ask Your Doctor Treatment Planning About AML Treatments Relapsed or Refractory AML Stem Cell Transplantation Acute Promyelocytic Leukemia (APL) Treatment Acute Monocytic Leukemia Treatment AML Treatment in Children AML Treatment in Older Patients 24 Part 3—About Clinical Trials 25 Part 4—Side Effects and Follow-Up Care Side Effects of AML Treatment Long-Term and Late Effects Follow-up Care Tracking Your AML Tests 30 Take Care of Yourself 31 Medical Terms This LLS Guide about AML is for information only.
    [Show full text]
  • Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
    ORIGINAL RESEARCH published: 15 June 2021 doi: 10.3389/fonc.2021.682658 Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients Gregorio Barilà, Laura Pavan, Susanna Vedovato, Tamara Berno, Mariella Lo Schirico, Massimiliano Arangio Febbo, Antonella Teramo, Giulia Calabretto, Cristina Vicenzetto, Vanessa Rebecca Gasparini, Anna Fregnani, Sabrina Manni, Valentina Trimarco, Samuela Carraro, Monica Facco, Francesco Piazza, Gianpietro Semenzato and Renato Zambello* Department of Medicine (DIMED), Hematology and Clinical Immunology Section, Padua University School of Medicine, Edited by: Padova, Italy Roberto Mina, Università degli Studi di Torino, Italy Reviewed by: The biology of plasma cell dyscrasias (PCD) involves both genetic and immune-related Mattia D’ Agostino, factors. Since genetic lesions are necessary but not sufficient for Multiple Myeloma (MM) University of Turin, Italy evolution, several authors hypothesized that immune dysfunction involving both B and T Michele Cea, University of Genoa, Italy cell counterparts plays a key role in the pathogenesis of the disease. The aim of this study *Correspondence: is to evaluate the impact of cornerstone treatments for Multiple Myeloma into immune Renato Zambello system shaping. A large series of 976 bone marrow samples from 735 patients affected by [email protected] PCD was studied by flow analysis to identify discrete immune subsets. Treated MM Specialty section: samples displayed a reduction of CD4+ cells (p<0.0001) and an increase of CD8+ This article was submitted to (p<0.0001), CD8+/DR+ (p<0.0001) and CD3+/CD57+ (p<0.0001) cells. Although these Hematologic Malignancies, findings were to some extent demonstrated also following bortezomib treatment, a more a section of the journal Frontiers in Oncology pronounced cytotoxic polarization was shown after exposure to autologous stem cell Received: 18 March 2021 transplantation (ASCT) and Lenalidomide (Len) treatment.
    [Show full text]
  • Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL Or ALL
    cells Article Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL Felix Korell 1,*, Sascha Laier 2, Sandra Sauer 1, Kaya Veelken 1, Hannah Hennemann 1, Maria-Luisa Schubert 1, Tim Sauer 1, Petra Pavel 2, Carsten Mueller-Tidow 1, Peter Dreger 1, Michael Schmitt 1 and Anita Schmitt 1 1 Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany; [email protected] (S.S.); [email protected] (K.V.); [email protected] (H.H.); [email protected] (M.-L.S.); [email protected] (T.S.); [email protected] (C.M.-T.); [email protected] (P.D.); [email protected] (M.S.); [email protected] (A.S.) 2 Institute of Clinical Transfusion Medicine and Cell Therapy (IKTZ), 89081 Heidelberg, Germany; [email protected] (S.L.); [email protected] (P.P.) * Correspondence: [email protected] Received: 9 April 2020; Accepted: 13 May 2020; Published: 15 May 2020 Abstract: Background: T lymphocyte collection through leukapheresis is an essential step for chimeric antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily pretreated patients who suffer from rapid progressive disease and receive T cell impairing medication. Methods: A total of 75 unstimulated leukaphereses were analyzed including 45 aphereses in patients and 30 in healthy donors. Thereof, 41 adult patients with Non-Hodgkin’s lymphoma (85%) or acute lymphoblastic leukemia (15%) underwent leukapheresis for CAR-T cell production.
    [Show full text]
  • Characterization of Immunophenotyping in ALL: a Single Center Study of Western India Dr
    DOI: 10.21276/sjams.2016.4.9.35 Scholars Journal of Applied Medical Sciences (SJAMS) ISSN 2320-6691 (Online) Sch. J. App. Med. Sci., 2016; 4(9C):3349-3354 ISSN 2347-954X (Print) ©Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com Original Research Article Characterization of Immunophenotyping in ALL: A Single Center Study of Western India Dr. Sandeeep K Jasuja1, Dr Sandhya Gulati2, Shraddha Patel3, Dr Nidhi Sharma4 1Asso. Professor and Head, Department of Medical Oncology, SMS MC & Attached Hospitals, Jaipur, Rajasthan, India 2Professor, Department of Pathology, SMS MC & Attached Hospitals, Jaipur, Rajasthan, India 3Observational Trainer, Department of Medical Oncology, SMS MC & Attached Hospitals, Jaipur, Rajasthan, India 4Assistant Professor, Department of Pathology, SMS MC & Attached Hospitals, Jaipur, Rajasthan, India *Corresponding author Dr. Sandeeep K Jasuja Email: [email protected] Abstract: This retrospective observational study was done among 227 ALL cases at a cancer treatment center in Western India. Data were collected retrospectively from hospital records during June 2015 to May 2016. Diagnosis of ALL was made based on the complete blood cell counts, peripheral blood smear/bone marrow aspirate smear and immunophenotyping study. Out of 227 ALL patients, 217 cases were of B-ALL, 8 cases were of T-ALL and 2 cases were of biphenotypic ALL. Of these 217 cases of B-ALL 190 (87.56) were pediatric age (range 0.5-15 years) and 27 (12.44) were adult (range 16-52 years). T-ALL cases were equally distributed in both age groups, 4 (50%) cases in pediatric age group (range 1-7 years)and 4 (50%) cases were adult (range 19-62 years).
    [Show full text]
  • Plasma-Cell-Dyscrasias-Sflc-Assay Executive
    Comparative Effectiveness Review Number 73 Effective Health Care Program Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias Executive Summary Background Effective Health Care Program Plasma cell dyscrasias (PCDs) are a group The Effective Health Care Program of neoplastic disorders characterized by was initiated in 2005 to provide the uninhibited expansion of a monoclonal valid evidence about the comparative population of malignant plasma cells.1 effectiveness of different medical Multiple myeloma (MM) is the most interventions. The object is to help common malignant plasma cell tumor, consumers, health care providers, accounting for about 1 percent of all and others in making informed cancer types,1 and the second most choices among treatment alternatives. common hematologic malignancy in Through its Comparative Effectiveness the United States. With an age-adjusted Reviews, the program supports incidence rate of 5.5 cases per 100,000 systematic appraisals of existing population,2 an estimated 19,900 new scientific evidence regarding diagnoses and 10,790 deaths due to treatments for high-priority health myeloma occurred in 2007, according conditions. It also promotes and to the American Cancer Society.3 Although generates new scientific evidence by the median survival has improved to identifying gaps in existing scientific 5 years with current standards of evidence and supporting new research. treatment,4 the annual costs of modern The program puts special emphasis therapies can range from $50,000 to on translating findings into a variety $125,000 per patient.5,6 of useful formats for different In PCDs, each abnormally expanded stakeholders, including consumers.
    [Show full text]
  • Immunophenotyping of Acute Leukaemias Immunophänotypisierung Akuter Leukämien
    Immunhämatologie Redaktion: G. Rothe Immunophenotyping of Acute Leukaemias Immunophänotypisierung akuter Leukämien T. Benter, R. Rätei, W.-D. Ludwig Summary: For nearly 100 years the classification of menden Einfluß gewonnen. Der Grund liegt in den blood cells and the diagnosis of leukaemia have been Fortschritten der Laser- und Computertechnologie, based on cytomorphological features after staining. aber auch an der Verfügbarkeit von Hunderten ver- Even in the era of molecular biology this is still es- schiedener monoklonaler Antikörper (moAB). die sential. Therapy of acute myeloid leukaemia (AML) is gegen eine Vielfalt von Antigenen hämatopoetischer mostly dependent on the interpretation of the morpho- Zellen gerichtet sind. logical appearance of blasts under the microscope. Cy- Dieser Übersichtsartikel fokussiert auf die Immun- tomorphology should also lead to a rational use of phänotypisierung von Patienten mit akuten Leukämien techniques like immunophenotyping, cytogenetics, flu- und zeigt den Einfluß auf die Diagnostik und Thera- orescence / situ hybridisation (FISH), and poly- pie. merase chain reaction (PCR). In the past two decades, the impact of immunophe- Schlüsselwörter: akute Leukämie: Immunophänoty- notyping by flow cytometry in the diagnosis and man- pisierung: Klassifikation von Leukämien. agement of acute leukaemia has expanded rapidly. This has been mainly attributed to significant advances in laser and computer technologies and the production of several hundred monoclonal antibodies (moAbs) to he gold standard for classifying acute myeloid a variety of antinens expressed by haematopoietic Tleukaemia (AML) has been based on morphologi- cells. cal, cytochemical, and iinmunophenotypic criteria as This review concentrates on immunophenotyping of defined by the French—American—British (FAB) sys- cells from patients with acute leukaemia and shows the tem 11-4].
    [Show full text]
  • Immunophenotyping of B-Acute Lymphoblastic Leukaemia
    IMMUNOPHENOTYPING OF B-ACUTE LYMPHOBLASTIC LEUKAEMIA Dr Lee Shir Ying Sr Consultant Haematologist Department of Laboratory Medicine National University Hospital Singapore Introduction • Case study illustrating the principles of immunophenotyping for B-ALL • MRD detection in B-ALL Cell characterization • Means of characterization: – Morphology, cytochemistry, immunohistochemistry, flow cytometry immunophenotyping – Characterization into: –Lineage, maturity, abnormality Flow Cytometry Technology • Simultaneous measurement of multiple physical characteristics of a single cell as the cell flows in suspension through a measuring device Definition • B-ALL: Neoplasm of precursors (lymphoblasts) committed to B-cell lineage • When blood and bone marrow are extensively involved, acute lymphoblastic leukemia (B-ALL) is appropriate • When disease is confined to mass with absent or minimal blood and marrow involvement, term lymphoblastic lymphoma (B-LBL) is used • If patient presents with mass lesion and blood and bone marrow involvement, 25% blasts in marrow defines leukemia (B-ALL) Case Study • 58-year-old man. No past medical history of note. • Referred for investigation of pancytopaenia and constitutional symptoms. • Also a paravertebral mass, which was biopsied (also sent for flow cytometry) • Full blood count – Total white cell count - 2.9 x 109/L – Haemoglobin - 7.7 g/dL – Platelet count - 23 x 109/L ➢ Bone marrow aspirate MGG stained ➢ Infiltrated by small uniform blast-like cells ➢ Fine chromatin, high N/C ratio, nucleoli present, irregular nuclear contours Bone marrow trephine: ➢ Hypercellular for age ➢ Marked decrease in trilineage haematopoiesis Sheets of darkly-stained cells with high N/C • Round to irregular nuclei • Evenly dispersed chromatin • Inconspicuous to small nucleoli PAX5 CD79a CD20 Morphology appears to be a straightforward B-cell acute lymphoblastic leukaemia, but....
    [Show full text]
  • Clearllab 10C Panel Markers and How They Are Combined
    WHITE PAPER ClearLLab 10C Panel Markers and how they are combined Mike Keeney London Health Sciences Centre, Victoria Hospital, London, ON, Canada Sandra Hernandez Beckman Coulter Inc. Life Sciences, Miami, FL 33196 IN THIS PAPER YOU WILL Experience the utility of the Discover the ClearLLab 10C Explore the power of optimizing ClearLLab 10C panel as an aid panel: the first 10-color CE-IVD your L&L immunophenotyping in the differential diagnosis of immunophenotyping reagents workflow with fewer steps, hematologically abnormal patients for assessing lymphoid and fewer tubes and more colors having or suspected of having myeloid populations certain hematopoietic neoplasms Introduction Flow cytometric immunophenotyping remains an indispensable tool for the diagnosis, classification, staging, and monitoring of hematologic neoplasms. There have been significant advances in flow cytometry instrumentation and availability of an expanded range of antibodies and fluorochromes that have improved the ability to identify different normal cell populations and recognize phenotypic aberrancies. ClearLLab 10C Panels consists of a set of four 10-Color reagents in dry unitized format, composed of antibodies directed against T, B, NK and Myeloid lineage antigens. These panels are designed to include the primary antibodies which are lineage oriented as per the 2006 Bethesda consensus. The combinations are intended to identify the leukocyte subpopulations that express these antigens alone or in specific co-expression patterns, and are designed to work with both normal samples and samples coming from any patient having or suspected of having the following hematopoietic neoplasms: chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS), and/or myeloproliferative neoplasms (MPN).
    [Show full text]
  • Correlation Between Flow Cytometry and Histologic Findings
    ORIGINAL ARTICLE Correlation between flow cytometry and histologic findings: ten year experience in the investigation of lymphoproliferative diseases Correlação entre citometria de fluxo e anatomia patológica: experiência de dez anos na investigação de doenças linfoproliferativas Alanna Mara Pinheiro Sobreira Bezerra1, Denise da Cunha Pasqualin1, João Carlos de Campos Guerra2, Marjorie Paris Colombini3, Elvira Deolinda Rodrigues Pereira Velloso2, Paulo Augusto Achucarro Silveira2, Cristovão Luis Pitangueira Mangueira1, Ruth Hissae Kanayama3, Sonia Tsukasa Nozawa3, Rodolfo Correia3, Ana Carolina Apelle1, Welbert de Oliveira Pereira3, Rodrigo Gobbo Garcia4, Nydia Strachman Bacal5 ABSTRACT follicular lymphoma; 15 patients with diffuse large B-cell lymphoma; 7 Objective: To demonstrate the advantages of correlating patients with small lymphocytic B-cell lymphoma/chronic lymphocytic flow cytometry immunophenotyping with the pathology/ leukemia; 3 patients with mantle cell lymphoma; 1 patient with immunohistochemistry of lymph nodes or nodules in the diagnosis Burkitt’s lymphoma; 1 patient with MALT type lymphoma; 1 patient of lymphoproliferative diseases. Methods: A retrospective study with post-transplant lymphoproliferative disease; 2 patients with high was carried out of 157 biopsy or fine-needle aspiration lymph nodes/ grade non-Hodgkin’s B-cell lymphoma; 1 patient with low grade non- nodule specimens taken from 142 patients, from 1999 and 2009. Hodgkin’s B-cell lymphoma not otherwise specified; 1 patient with The specimens were simultaneously studied with flow cytometry Hodgkin’s lymphoma; and 12 patients with B-cell non-Hodgkin’s and pathology at Hospital Israelita Albert Einstein. The specimens lymphoma not otherwise specified. Conclusion: Flow cytometry were prepared in hematoxylin/eosin, Giemsa, or monoclonal antibody adds to the results of morphologic and immunohistochemical studies, stained slides for detecting specific antibodies for the purposes facilitating a rapid and accurate diagnosis of lymphoproliferative of pathology/immunohistochemical analysis.
    [Show full text]
  • Development of a Regional Flow Cytometry Center for Diagnosis Of
    Leukemia (2005) 19, 323–325 & 2005 Nature Publishing Group All rights reserved 0887-6924/05 $30.00 www.nature.com/leu EDITORIAL Development of a regional flow cytometry center for diagnosis of childhood leukemia in Central America SC Howard1,2,3, D Campana1,2,3,7, E Coustan-Smith1, FG Antillon3,4, M Bonilla3,5,LFu3,6, C-H Pui1,2,3,7, RC Ribeiro1,2,3, JA Wilimas1,2,3 and R Lorenzana8 1Department of Hematology-Oncology, St Jude Children’s Research Hospital, Memphis, TN, USA; 2Department of Pediatrics, University of Tennessee College of Medicine, Memphis, TN, USA; 3International Outreach Program, St Jude Children’s Research Hospital, Memphis, TN, USA; 4Unidad Nacional de Oncologı´a Pedia´trica, Guatemala City, Guatemala; 5Hospital Benjamin Bloom, San Salvador, El Salvador; 6Hospital Escuela, Tegucigalpa, Honduras; 7Department of Pathology, St Jude Children’s Research Hospital, Memphis, TN, USA; and 8Laboratorio de Patologı´a y Citometrı´a de Flujo, Guatemala City, Guatemala Leukemia (2005) 19, 323–325. doi:10.1038/sj.leu.2403624 From April 30, 1998 to December 31, 2002, specimens from pediatric patients with suspected leukemia at the Hospital Assessment of immunophenotype and DNA content of leukemia Escuela (Tegucigalpa, Honduras), the Hospital Benjamin Bloom is important for diagnosis and risk assessment, but requires (San Salvador, El Salvador), and the Unidad Nacional de costly equipment, reagents and technical expertise. Samples Oncologı´a Pedia´trica (Guatemala City, Guatemala) were from 1118 children in Central America were sent for flow analyzed by the Pathology and Flow Cytometry Laboratory in cytometric examination to a reference laboratory in Guatemala Guatemala City.
    [Show full text]
  • Immunophenotyping of Acute Lymphoblastic Leukaemia In
    688 J Clin Pathol 1999;52:688–692 Immunophenotyping of acute lymphoblastic J Clin Pathol: first published as 10.1136/jcp.52.9.688 on 1 September 1999. Downloaded from leukaemia in routinely processed bone marrow biopsy specimens B Toth, M Wehrmann, E Kaiserling, H-P Horny Abstract c-ALL, 8 T-ALL, 2 B-ALL, 2 u-ALL). Aims—To assess the value of immunophe- Immunostaining of more than 10% of blast notyping of acute lymphoblastic leukae- cells in at least one case was found with 19 mia (ALL) in routinely processed bone of the 26 antibodies. The most sensitive marrow trephine biopsy specimens and to lineage specific antibodies for diagnosis establish a minimum panel of antibodies were found to be anti-CD10 for c-ALL (22/ to assess lymphoid lineage and enable dif- 23) and âF1 for T-ALL (6/8). Expression of ferentiation from acute myeloid leukae- aberrant antigens was fairly common—for mia. example, 7/23 cases of c-ALL stained with Methods—45 routinely processed bone antibodies against T cell associated anti- marrow biopsy specimens (formalin gens. fixed, paraYn embedded and mildly de- Conclusions—Immunohistochemical in- calcified in EDTA) reported to contain vestigation of routinely processed bone leukaemic infiltrates on the basis of cyto- marrow biopsy specimens enables reliable morphological and enzyme-cytochemical detection of ALL subtypes c-ALL and analysis of bone marrow smears (22 T-ALL. A minimum panel of antibodies, c-ALL, 11 T-ALL, 2 B-ALL, 10 u-ALL against TdT, CD34, myeloperoxidase, lys- (unclassified)) were immunostained by ozyme, CD10, CD79a, and CD20, and the the ABC method with a broad panel of 26 antibody âF1, is proposed for the immu- antibodies against various haemopoietic nophenotyping of acute leukaemia.
    [Show full text]